References
- Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet βcells in diabetes. J Biol Chem. 2004; 279(41): 42351-42354.
- Hari Kumar KVS, Modi KD. Twins and endocrinology. Indian J Endocrinol Metab. 2014; 18(Suppl 1): S48-S52.
- Bramswig NC, Kaestner KH. Epigenetics and diabetes treatment: An unrealized promise? Trends Endocrinol Met. 2012; 23(6): 286-291.
- Kommoju U, Reddy BM. Genetic etiology of type 2 diabetes mellitus: A review. Int J Diab Dev Ctries. 2011; 31(2): 51-64.
- Lyssenko V, Laakso M. Genetic screening for the risk of type 2 diabetes: Worthless or valuable? [Research Support, Non-U.S. Gov’t Review]. Diabetes Care. 2013; 36(Suppl 2): S120-S126.
- Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. [10.1038/ 414782a]. Nature. 2001; 414(6865): 782-787.
- Ling C, Groop L. Epigenetics: A molecular link between environmental factors and type 2 diabetes. Diabetes. 2009; 58(12): 2718-2725.
- Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Gene Dev. 2009; 23(7): 781-783.
- Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007; 128(4): 669-681.
- Tsai H-C, Baylin SB. Cancer epigenetics: Linking basic biology to clinical medicine. Cell Res. 2011; 21(3): 502-517.
- Patra SK, Deb M, Patra A. Molecular marks for epigenetic identification of developmental and cancer stem cells. Clin Epigenetics. 2011; 2(1): 27-53.
- Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. [Research Support, Non-U.S. Gov’t Review]. Trends Biochem Sci. 2006; 31(2): 89-97. 10.1016/j.tibs.2005.12.008.
- Keating ST, El-Osta A. Epigenetic changes in diabetes. [Research Support, Non-U.S. Gov’t Review]. Clin Genet. 2013; 84(1): 1-10. 10.1111/cge.12121.
- Bird A. DNAmethylation patterns and epigenetic memory. [Research Support, Non-U.S. Gov’t Review]. Genes Dev. 2002; 16(1): 6-21.
- Clouaire T, Stancheva I. Methyl-CpG binding proteins: Specialized transcriptional repressors or structural components of chromatin? Cell Mol Life Sci. 2008; 65(10): 1509-1522.
- Chavali V, Tyagi N, Tyagi SC, Mishra PK. MiR-133 as an epigenetic regulator of diabetic heart failure. FASEB J. 2012; 26(1_MeetingAbstracts): 1057.1022.
- Adela R, Banerjee SK. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: A translational prospective. J Diabetes Res. 2015; 2015: 4090842. 101155/2015/490842.
- Lindahl B. The story of growth differentiation factor 15: another piece of the puzzle. Clin Chem. 2013; 59(11): 1550-1552.
- Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fribrilation (ARISTOTLE) trial. Circulation; 2014; 130(21): 1847-1858.
- Al-Moghrabi N, NofelA, Al-Yousef N, Madkhali S, Bin Amer SM, Alaiya A, et al. The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females. [Research Support, Non-U.S. Gov’t]. BMC Cancer. 2014; 14: 830. 10.1186/1471-2407-14-830.
- Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Blood. 2011; 117(2): 553-562.
- Brevetti G, Schiano V, Chiariello M. Cellular adhesion molecules and peripheral arterial disease. (Review). Vasc Med. 2006; 11(1); 39-47.
- Park JG, Yoo JY, Jeong SJ, Choi JH, Lee MR, Lee MN, et al. Peroxiredoxin 2 deficiency exacerbates atherosclerosis in apolipoprotein E-deficient mice. [Research Support, Non-U.S. Gov’t]. Circ Res. 2011; 109(7): 739-749.
- Brown CO, Schibler J, Fitzgerald MP, Singh N, Salem K, Zhan F, et al. Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma. Leukemia Res. 2013; 37(8): 963-969.
- Scoumanne A, Chen X. Protein methylation: A new regulator of the p53 tumor suppressor. Histol Histopathol. 2008; 23(9): 1143-1149.
- El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006; 4(3): 369-380.
- Friberg E, Orsini N, Mantzoros C, Wolk A. Diabetes mellitus and risk of endometrial cancer: A meta-analysis. Diabetologia. 2007; 50(7): 13651374.
- HuxleyR, Ansary-MoghaddamA, Berringtonde Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. (Meta-Analysis). Br J Cancer. 2005; 92(11): 2076-2083.
- Larsson S, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: A metaanalysis. Diabetologia. 2006;49(12):2819-2823.
- Larsson S, Wolk A. Diabetes mellitus and incidence of kidney cancer: A meta-analysis of cohort studies. Diabetologia. 2011; 54(5): 1013-1018.
- Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer I. 2005; 97(22): 1679-1687.
- Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A meta analysis. Int J Cancer. 2007; 121(4): 856-862.